TBC1 domain family member 9Genealiases: GRAMD9 · MDR1
Q-omics provides the consensus-scored TBC1D9 profile across patient tissues and cancer cell-line models. TBC1D9 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, TBC1D9 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, TBC1D9 RNA expression shows 20,228 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, and UVM as cancer lineages where TBC1D9 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TBC1D9 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TBC1D9 survival associations across molecular data types. TBC1D9 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (7) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TBC1D9 RNA expression–survival associations across cancer types. High TBC1D9 expression shows unfavorable associations in ACC, but favorable associations in KIRC, BRCA, HNSC, MESO and UCS. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for TBC1D9 RNA expression.
This table summarizes TBC1D9 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 3. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for TBC1D9. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TBC1D9 shows lower tumor expression in KIRC, COAD, KIRP, LUAD and LUSC and higher tumor expression in BRCA. The KIRC box plot shows higher TBC1D9 RNA expression in normal versus tumor tissue (log2 FC = −1.118, t-test p < 0.001).
This table shows molecular features associated with TBC1D9 in patient tissues and cancer cell lines. In patient samples, TBC1D9 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, TBC1D9 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and LUNG_NSCLC_LUAD.
